Tuesday, July 7, 2020

This Company Wants to Rewrite the Future of Genetic Disease

Tessera Therapeutics is developing a new class of gene editors capable of precisely plugging in long stretches of DNA—something that Crispr can't do.

from Wired https://ift.tt/38B7ti7
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)